Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Inés Luis de Redín"'
Autor:
Iván Peñuelas, Alfonso Calvo, Daniel Alberto Allemandi, Inés Luis de Redín, Francisco Exposito, Maite Agüeros, Juan M. Irache, Juan Manuel Llabot, María Collantes
Publikováno v:
Drug Delivery and Translational Research. 10:635-645
Bevacizumab (as other monoclonal antibodies) has now become a mainstay in the treatment of several cancers in spite of some limitations, including poor tumour penetration and the development of resistance mechanisms. Its nanoencapsulation may be an a
Autor:
Carolina Boiero, María José Dávila Caballero, Juan M. Irache, Inés Luis de Redín, Maite Agüeros, Daniel Alberto Allemandi, Juan Manuel Llabot
Publikováno v:
Journal of Drug Delivery Science and Technology. 52:379-385
The aim of this work was to study the preparation process and the in vitro release of human serum albumin nanoparticles stabilized by Gantrez® ES-425, which was loaded with antiangiogenic drugs (suramin and bevacizumab). Nanoparticles were prepared
Autor:
Priscila Valera Guerra, Juan M. Irache, Rafaela de Siqueira Ferraz-Carvalho, Inés Luis de Redín, Cláudia Brodskyn, Juliana de Souza Rebouças, Carlos Gamazo, Nereide S. Santos-Magalhães, Marcela Araújo Pereira
Publikováno v:
European Journal of Pharmaceutics and Biopharmaceutics. 127:51-60
Cashew nut allergy is the second most commonly reported tree nut allergy. Traditional allergen immunotherapy presents several clinical drawbacks that can be reduced by using nanoparticles-based allergen-delivery systems, modulating the immune respons
Autor:
Juan Manuel Llabot, Sergio Recalde, Juan M. Irache, Maite Agüeros, Inés Luis de Redín, Alfredo García-Layana, Carolina Boiero, Daniel Alberto Allemandi
Publikováno v:
Experimental eye research. 185
Corneal neovascularization (CNV) is associated with different ocular pathologies, including infectious keratitis, trachoma or corneal trauma. Pharmacological treatments based on the topical application of anti-VEGF therapies have been shown to be eff
Autor:
Rocío Ramos, Inés Luis de Redín, Daniel Alberto Allemandi, Maite Agüeros, Juan M. Irache, Juan Manuel Llabot, Carolina Boiero, Iván Peñuelas, María Cristina Martínez-Ohárriz
Publikováno v:
International journal of pharmaceutics. 541(1-2)
Bevacizumab-loaded nanoparticles (B-NP) were prepared by a desolvation process followed by freeze-drying, without any chemical, physical or enzymatic cross-linkage. Compared with typical HSA nanoparticles cross-linked with glutaraldehyde (B-NP-GLU),